Boehringer, Vanderbilt U to develop cancer MCL1 inhibitors in third team-up

Cancer cells are different from normal cells in that they can avoid a naturally programmed cell death process known as apoptosis and grow almost indefinitely. In their third collaboration, Boehringer Ingelheim and Vanderbilt University have their eyes on a target that helps cancer cells evade death.

• Source: fiercebiotech
• 457
• March 16, 2018